UNSPSC 51322005: Xinomiline

This classification denotes an anti-lipidemic agent with the molecular formula C5H10N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q22EPG4O8, chemically known as 4,5-dihydro-4,4-dimethyl-2-oxazolamin but generally known as xinomiline, which bears US NIH Compound Identifier 3085023. European Medicines Agency schedules Xinomiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00115MIG.

UNSPSC 51322005 Xinomiline is a Commodity code capturing emergency and critical-care pharmaceutical supplies that state and local governments procure for fire rescue operations, health agencies, and cooperative purchasing programs. State and local buyers under this code are soliciting specific advanced life support medications, generic pharmaceuticals, and over-the-counter products for direct distribution to emergency services and public health facilities. Issuing bodies include city fire departments and public safety agencies (such as the City of Tampa), state health commissions (such as the Texas Health and Human Services Commission), and multistate cooperative purchasing consortia (such as the Minnesota Multistate Cooperative Purchasing Alliance). The work involves supplying individual medication units with strict expiration and quality requirements, managing cold-chain logistics where applicable, and complying with FDA standards, Good Manufacturing Practices, Drug Supply Chain Security Act certification, and OSHA Hazard Communication Standards for safety data sheets.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa's Purchasing Department issued an invitation to bid (26P00188) for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026, seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue with an estimated contract value of $40,000 and a one-year term plus renewal options. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on April 3, 2026, to explore vendor capabilities for direct-to-manufacturer prescription programs without pharmacy benefit manager intermediation. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing vehicle, posted an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with performance penalties of $200 to $1,500 per violation and a 3 percent administrative fee on all contract purchases.